Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968430 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
A Phase 3 study of Hypertension, sponsored by Mineralys Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 1,076
- Enrollment target
- 20
- Study locations
NCT05968430 is a Phase 3 study of Hypertension that is active but no longer recruiting, run by Mineralys Therapeutics. The registered enrollment target is 1,076 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05968430, a Phase 3 study of Hypertension, is active but no longer recruiting, sponsored by Mineralys Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,076 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
Conditions Studied
Interventions
- DRUG Placebo
- DRUG lorundrostat
Study Locations (20)
California
- Entertainment Medical Group, Inc - Beverly Hills
- CA Institute of Renal Research, CA - Chula Vista
- Amicis Research Center - Vacaville - Fairfield
- Amicis Research Center - Granada Hills - Granada Hills
- Marvel Clinical Research 002, LLC - Huntington Beach
- University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
- Clinical Trials Research (CTR) - Lincoln - Lincoln
- Academic Medical Research Institute (AMRI) - Los Angeles - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Amicis Research Center - Mission Hills - Northridge
- Amicis Research Center-Northridge - Northridge
- Northridge Clinical Trials - Northridge
- Pasadena Clinical Trials - Pasadena
Arizona
- Chandler Clinical Trials - Chandler
- Arizona Kidney - Glendale
- AKDHC Medical Research Services, AZ - Phoenix
- Noble Clinical Research - Tucson
- Del Sol Research Management, LLC - Tucson
Alabama
- Accel Research Sites (ARS) - Birmingham Clinical Research Unit - Birmingham
- G & L Research LLC - Foley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,076 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968430
The ClinicalTrials.gov registry entry for NCT05968430 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,076 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower). The listed sponsor is Mineralys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05968430 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05968430 about?
NCT05968430 is a clinical study titled "Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension". This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
What is the current status of trial NCT05968430?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,076 participants. The study started on 2023-07-14. Estimated completion is 2026-12.
What conditions does trial NCT05968430 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT05968430?
The interventions under investigation include: Placebo (DRUG), lorundrostat (DRUG).
Who is sponsoring clinical trial NCT05968430?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05968430 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.